Insulin resistance in pathogenesis of type 2 diabetes mellitus
https://doi.org/10.14341/2072-0351-6248
Abstract
This review focuses on the mechanisms of impaired sensitivity to insulin associated withevolution of carbohydrate metabolism disorders from enhanced fasting glycemia (EFG) to impaired glucose tolerance (IGT) and type 2 diabetes.Disturbances of glucose utilization at the receptor and post-receptor levels are considered along with the role of glucose and lipotoxicity. Original dataon insulin resistance (IR) in patients with disorders of carbohydrate metabolism are presented. Insulin sensitivity in DM2, EFG and IGT is shownto be 50, 25 and 15% lower respectively than in normal subjects. M-index positively correlates with BMI and quality of metabolic control (HbA1cand triglyceride levels). The differences in clinical and biochemical characteristics of DM2 patients are analysed depending on the degree of IR.Adiponectin and resistin levels in DM2 are shown to be lower than in healthy subjects while TNF-a and proinsulin levels increase. Therapy withmetformin, pyoglitazone, and insulin improves insulin sensitivity even in patients with early disturbances of carbohydrate metabolism. It is concludedthat intensive hypoglycemic therapy should be initiated before marked deterioration of insulin sensitivity developed.
References
1. Himsworth H.P., Kerr R.B. Insulin-sensitive and Insulin-insensitive types diabetes mellitus // Clin. Sci. - 1939. - № 4. - Р. 119-152.
2. Дедов И.И., Шестакова М.В. Сахарный диабет. - М.: Универсум Паблишинг. - 2003.
3. Del Prato S., Leonetti F., Matsuda M., DeFronzo R.A. et al. Effect of sustained physiologic hyperinsulinemia and hyperglycaemia on insulin secretion and insulin sensitivity in man // Diabetologia. - 1994. - № 37. - Р. 1025-1035.
4. Балаболкин М.И., Клебанова Е.М. Инсулинорезистентность в патогенезе сахарного диабета 2 типа // Сахарный диабет. - 2001. - № 1. - С. 28-37.
5. Шестакова М.В., Брескина О.Ю. Инсулинорезистентность: патофизиология, клинические проявления, подходы к лечению // Consilium medicum. - 2002. - № 10.
6. Kumar S., O'Rahily S. Insulin Resistance. Insulin action and its disturbances in diseases // John Wiley & Sons, Ltd. - 2005.
7. Nathan D.M., Davidson M.B., DeFronzo R.A. et al. Impaired fasting glucose and impaired glucose tolerance // Diabetes Care. - 2007. - № 30. - Р. 753-759.
8. Reaven G.M. Role of insulin resistance in human disease (syndrome X): an expanded definition // Annual Review of Medicine. - 1993. - № 44. - Р. 121-131.
9. Балаболкин М.И. Диабетология. - М.: Медицина. - 2000.
10. DeFronzo R.A. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM // Diabetes. - 1988. - № 37. - Р. 667-687.
11. Abel E.D., Peroni O., Kim J.K., Kim Y.В., Boss O., Hadro E., Minnemann Т., Shulman G. I., Kahn В. B. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver // Nature. - 2001. - № 409. - Р. 729-733.
12. Roden M., Price Т.В., Perseghin G., Petersen K.F., Rothman D.L., Cline G.W., Shulman G.I. Mechanism of free fatty acid-induced insulin resistance in humans // J. Clin. Invest. - 1996. - № 97. - Р. 2859-2865.
13. Elrick H., Stimmler L., Hlad C.J., Turner D.A. Plasma insulin responses to oral and intravenous glucose administration // J. Clin. Endocrinol Metab. - 1964. - № 24. - Р. 1076-1082.
14. Clark M.G., Wallis M.G., Barrett E.J., Vincent M.A., Richards S.M., Clerk L.H., Rattigan S. Blood flow and muscle metabolism: a focus on insulin action // Am. J. Physiol. - 2003. - № 284. - Р. E241-258.
15. Дедов И.И., Балаболкин М.И. Инсулиновая резистентность в патогенезе сахарного диабета типа 2 и медикаментозная возможность ее преодоления // Врач. - 2006. - № 11.
16. Olefsky J.M. The insulin receptor. A multifunctional protein // Diabetes. - 1990. - № 39. - Р. 1009-1016.
17. White M.F. IRS proteins and the common path to diabetes // Am J Physiol Endocrinol Metab. - 2002. - № 283. - Р. E413-422.
18. Kimber W.A., Deak M., Prescott A.R., Alessi D.R. Interaction of the protein tyrosine phosphatase PTPL1 with the PtdIns(3,4)P2-binding adaptor protein TAPP1 // Biochem. J. - 2003. - № 376. - Р. 525-535.
19. Heller-Harrison R.A., Morin M., Guilherme A., Czech M.P. Insulinmediated targeting of phosphatidylinositol 3-kinase to GLUT4-containing vesicles // J. Biol. Chem. - 1996. - № 271. - Р. 10200-10204.
20. Whiteman E.L., Cho H., Birnbaum M.J. Role of Akt/protein kinase В in metabolism // Trends Endocrinol Metab. - 2002. - № 13. - Р. 444-451.
21. Ueki K., Fruman D.A., Yballe С.M., Fassaur M., Klein J., Asano Т., Cantley L.C., Kahn C.R. Positive and negative roles of p85alpha and p85beta regulatory subunits of phosphoinositide 3-kinase in insulin signaling // J. Biol. Chem. - 2003. - № 278. - Р. 48453-48466.
22. Joost H. G., Bell G. I., Best J.D., Birnbaum M.J., Charron M.J., Chen Y.Т., Doe ge H., James D.E., Lodish H.F., Moley К.H. et al. Nomenclature of the GLUT/SLC2A family of sugar/polyol transport facilitators // Am. J. Physiol. - 2002. - № 282. - Р. E974-976.
23. Barzilai N., Rossetti L. Role of glucokinase and glucose-6-phosphatase in the acute and chronic regulation of hepatic glucose fluxes by insulin // Biol. Chem. - 1993. - № 268. - Р. 25019-25025.
24. Printz R.L., Koch S., Potter L.R., O'Doherty R.M., Tiesinga J. J., Moritz S., Granner D.K. Hexokinase II mRNA and gene structure, regulation by insulin, and evolution // J. Biol. Chem. - 1993. - № 268. - Р. 5209-5219.
25. Cohen P., Frame S. The renaissance of GSK3 // Nat. Rev. Mol. Cell. Biol. - 2001. - № 2. - Р. 769-776.
26. Harris R.A., Bowker-Kinley M.M., Huang B., Wu P. Regulation of the activity of the pyruvate dehydrogenase complex // Adv. Enzyme Regul. - 2002. - № 42. - Р. 249-259.
27. Kahn S.E. The relative contributions of insulin resistance and beta-cell dysfunction to the patophysiology of Type 2 diabetes // Diabetologia. - 2005. - № 48. - Р. 3-19.
28. Reaven G.M. Role of insulin resistance in human disease // Diabetes. - 1988. - № 37. - Р. 1595-1607.
29. Cassell P.G., Jackson A.E., North B.V., Evans J.C., Syndercombe-Court D., Phillips C., Ramachandran A., Snehalatha C., Gelding S.V., Vijayaravaghan S., Curtis D., Hitman G.A. Haplotype combinations of calpain 10 gene polymorphisms associate with increased risk of impaired glucose tolerance and type 2 diabetes in South Indians // Diabetes. - 2002. - № 51. - Р. 1622-1628.
30. Haffner S.M., Karhapaa P., Mykkanen L., Laakso M. Insulin resistance, body fat distribution, and sex hormones in men // Diabetes. - 1994. - № 43. - Р. 212-219.
31. Peiris A.N., Struve M.F., Mueller R.A., Lee M.B., Kissebah A.H. et al. Glucose metabolism in obesity: influence of body fat distribution // J. Clin. Endocrinol. Metab. - 1988. - № 67 (4). - Р. 760-767.
32. Jazet I. M., Pijl H., Meinders A. E. Adipose tissue as an endocrine organ: impact on insulin resistance // Neth. J. Med. - 2003. - № 61 (6). - Р. 194-212.
33. Fasshauer M., Paschke1 R. Regulation of adipocytokines and insulin resistance // Diabetologia. - 2003. - № 46. - Р. 1594-1603.
34. Yki-Järvinen H. Glucose toxicity // Endocr. Rev. - 1992. - № 11. - Р. 415-431.
35. McGarry J.D., Dobbins R.L. Fatty acids, lipotoxicity and insulin resistance // Diabetologia. - 1999. - № 42. - Р. 128-138.
36. DeFronzo R.A., Tobin J.D., Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance // American Journal of Physiology. - 1979. - № 237 (3). - Р. E214-223.
37. Matthews D.R., Hosker J.P., Rudenski A.S., Turner R.C. et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentration in man // Diabetologia. - 1985. - № 28. - Р. 412-419.
38. Wallace T.M., Levy J.C., Matthews D.R. Use and abuse of HOMA modeling // Diabetes Care. - 2004. - № 27. - Р. 1487-1495.
39. Nuutila P., Knuuti M.J., Maki M., Yki-Jarvinen H. et al. Gender and insulin sensitivity in the heart and in skeletal muscles. Studies using positron emission tomography // Diabetes. - 1996. - № 44 (1). - Р. 31-36.
40. DeFronzo R.A., Bonadonna R.S., Ferrannini E. Pathogenesis of NIDDM. A balanced overview // Diabetes Care. - 1992. - № 15. - Р. 318- 368.
41. Frayn K.N. Visceral fat and insulin resistance - causative or correlative? // Br J Nutr. - 2000. - № 83 (Suppl. 1). - S71-77.
42. Rossetti L. Glucose toxicity: the implications of hyperglycemia in the pathophysiology of diabetes mellitus // Clin. Invest. Med. - 1995. - № 18. - Р. 255-260.
43. Алгоритмы специализированной медицинской помощи больным сахарным диабетом (под редакцией Дедова И.И., Шестаковой М.В.). Издание четвертое, дополненное. - М., 2009. - 103 с.
44. Pittas A.G., Joseph N.A. Adipocytokines and insulin resistance // J. Clin. Endocrinol. Metab. - 2004. - № 89. - Р. 447-452.
45. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) // Lancet. - 1998. - № 352. - Р. 854-865.
46. United Kingdom Prospective Diabetes Study 24: a 6-years, randomized, controlled trial comparing sulfonylurea, insulin and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy // Ann. Intern. Med. - 1998. - № 128 (3). - Р. 165-175.
47. Knowler W.C., Barrett-Connor E., Fowler S.E. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin // N.Engl. J. Med. - 2002. - № 346. - Р. 393-403.
48. Semple R.K., Chatterjee V.K., O'Rahilly S. PPAR gamma and human metabolic disease // J. Clin. Invest. - 2006. - № 116. - Р. 581-589.
Review
For citations:
Mayorov A.Yu. Insulin resistance in pathogenesis of type 2 diabetes mellitus. Diabetes mellitus. 2011;14(1):35-45. (In Russ.) https://doi.org/10.14341/2072-0351-6248
Views:
11901
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
